Intraocular chemotherapy for vitreoretinal lymphoma: A review

Vitreoretinal lymphomas are rare ocular cancers, and the subset of primary central nervous system lymphomas that are based in the posterior eye. These tumours are challenging to treat, and today management generally involves a multispecialty team coordinating a treatment protocol that may include in...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & experimental ophthalmology 2020-03, Vol.48 (2), p.240-248
Main Authors: Kvopka, Michael, Lake, Stewart R., Smith, Justine R.
Format: Article
Language:English
Subjects:
Autografts
Central nervous system
Chemotherapy
Clinical trials
drug therapy
eye
Immunosuppressive agents
Lymphoma
Metabolites
Methotrexate
Monoclonal antibodies
Radiation
retina
Rituximab
Stem cell transplantation
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vitreoretinal lymphomas are rare ocular cancers, and the subset of primary central nervous system lymphomas that are based in the posterior eye. These tumours are challenging to treat, and today management generally involves a multispecialty team coordinating a treatment protocol that may include intraocular chemotherapy, ocular irradiation, systemic chemotherapy and/or autologous stem cell transplantation. The ophthalmologist has specific responsibility for the intraocular chemotherapy, which is delivered to the eye by intravitreal injection. The most commonly injected drugs are methotrexate—an anti‐metabolite—and rituximab—an anti‐human B cell monoclonal antibody. A range of intraocular chemotherapy treatment schedules have been described in the medical literature, although to date there have been no randomized clinical trials of these schedules. In this article, we review the development and current status of intraocular chemotherapy for vitreoretinal lymphoma.
ISSN:1442-6404
1442-9071
DOI:10.1111/ceo.13668